By Michael Dabaie
AstraZeneca PLC (AZN) and FibroGen Inc. (FGEN) said roxadustat Phase III program pooled analyses showed positive efficacy and no increased cardiovascular risk in patients with anemia from chronic kidney disease.
FibroGen shares turned positive after trading down earlier in the session, recently up 9.5%, to $41.56. AstraZeneca ADRs also turned positive, recently up 0.6%, at $47.09.
In non dialysis-dependent patients receiving roxadustat, the risk of major adverse CV events, defined as all-cause mortality, stroke and myocardial infarction, MACE+, which is defined as MACE, unstable angina requiring hospitalization and congestive heart failure requiring hospitalization, and all-cause mortality was comparable to placebo, the companies said.
In incident dialysis patients, roxadustat had a lower risk of MACE and MACE+ and showed a trend towards lower risk of all-cause mortality relative to epoetin alfa.
Write to Michael Dabaie at firstname.lastname@example.org
(END) Dow Jones Newswires
November 08, 2019 15:04 ET (20:04 GMT)Copyright (c) 2019 Dow Jones & Company, Inc.